Drugs / Verdinexor
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | primary organ-specific lymphoma | 2014-02-26 | “Verdinexor (KPT-335) has been submitted to the FDA for approval in dogs with newly diagnosed or relapsed non-Hodgkin's lymphomas.” karyopharm.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02431364 | May → Oct 2015 | — | Karyopharm Therapeutics Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-08-07 | Karyopharm Therapeutics Inc | Regulatory Karyopharm Therapeutics Reports Second Quarter Financial Results for 2014 karyopharm.com ↗
The use of Verdinexor to treat canine lymphoma has been designated a "minor use" in accordance with the Minor Use Minor Species (MUMS) Act. |
| 2012-11-12 | Karyopharm Therapeutics Inc | Results Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) karyopharm.com ↗
When we treated the mice with SINE compounds given by mouth, we were able to reduce the level of kidney disease, associated pathogenic autoantibodies, and the plasma cells that produce them. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verdinexor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02431364 ↗ |
| Known as | KPT-335 | “Oral Verdinexor (KPT-335)” NCT02431364 ↗ |
| Modality | Small molecule | — CHEMBL3545187 ↗ |
| Route | Oral | “Route of administration: oral” NCT02431364 ↗ |